


FORM PTO-1449

U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICEATTY. DOCKET NO.
SCIOS.017AAPPLICATION NO.
09/809,545INFORMATION DISCLOSURE STATEMENT
BY APPLICANT

(USE SEVERAL SHEETS IF NECESSARY)

APPLICANT
Stanton et al.FILING DATE
March 14, 2001GROUP
Unknown

TECH CENTER 1600/2900

JUN 04 2002

RECEIVED

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE (IF APPROPRIATE)

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
							YES	NO
<i>L</i>	1.	WO 00/11942	09.03.03 3.9.00	PCT-WO	—	—		
<i>L</i>	2.	WO 00/35473	22.06.00 6.22.00	PCT-WO	—	—		

EXAMINER
INITIAL

OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.)

<i>L</i>	3.	Database EBI/SWALL 'online! (March 1, 2002) Cros et al. "Gene expression alterations revealed by suppression subtractive hybridization in rat soleus muscle disuse atrophy: Database accession no. Q8VD50XP002195683
<i>L</i>	4.	Stanton et al., "Altered Patterns of Gene Expression in Response to Myocardial Infarction" Circ. Res. 86(9):939:945 (March 2000)
<i>L</i>	5.	Stanton et al., "Cardiac Gene Expression Profiling in rat Myocardial Infarction Using DNA Microarrays", Circulation, American Heart Association 98(17)SUPP::1746 (October 1998)
<i>L</i>	6.	Stanton, Lawrence "Altered transcriptional responses in myocardial infarction "Cardiovascular Genomics 1-8(January 30, 2000)
<i>L</i>	7.	Willenbrock: "Regulation of cardiac adrenomedullin-mRNA in different stages of experimental heart failure: Life Sciences 65(21):2247-2249 (Discussion) (1999)

EXAMINER

DATE CONSIDERED

3/22/03

*EXAMINER: INITIAL IF CITATION CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED, INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.